UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 65

Sortiert nach

Abstract P1-08-18: Impact of gene expression profile testing for lymph node positive (LN+) , hormone receptor positive (HR+), HER2 negative (HER2-) breast cancer (BC) patients on the use of adjuvant chemotherapy in a large community cancer center

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-08-18

2022

Volltextzugriff (PDF)

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2015-07, Vol.373 (3), p.209-219

2015

Volltextzugriff (PDF)

Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region

Frontiers in oncology, 2023-01, Vol.12, p.975473-975473

2023

Volltextzugriff (PDF)

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

Cancer medicine (Malden, MA), 2021-09, Vol.10 (17), p.5748-5756

2021

Volltextzugriff (PDF)

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

Breast cancer research and treatment, 2021-07, Vol.188 (2), p.449-458

2021

Volltextzugriff (PDF)

Tumor Treating Fields (TTFields) Therapy with Standard of Care in Metastatic Non-small Cell Lung Cancer Following Progression on or after Platinum Therapy: Global, Randomized, Pivotal Phase 3 LUNAR Study

International journal of radiation oncology, biology, physics, 2024-01, Vol.118 (1), p.e9-e10

2024

Volltextzugriff (PDF)

Abstract P1-18-13: Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC) participating in the PALOMA trials

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-18-13

2022

Volltextzugriff (PDF)

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

The oncologist (Dayton, Ohio), 2021-08, Vol.26 (8), p.e1327-e1338

2021

Volltextzugriff (PDF)

1418P Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study

Annals of oncology, 2023-10, Vol.34, p.S810-S810

2023

Volltextzugriff (PDF)

7MO Sotorasib in KRAS G12C-mutated advanced non-small cell lung cancer (aNSCLC): Overall survival (OS) data from the global expanded access program (EAP study-436)

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S40-S41

2023

Volltextzugriff (PDF)

Circulating tumor DNA-based genomic profiling of small bowel adenocarcinoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3523-3523

2021

Volltextzugriff (PDF)

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810)

Lung cancer (Amsterdam, Netherlands), 2008-05, Vol.60 (2), p.259-263

2008

Volltextzugriff (PDF)

Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA9005-LBA9005

2023

Volltextzugriff (PDF)

Predictors of clinical outcomes of resected ampullary adenocarcinoma: A single-institution experience

European journal of surgical oncology, 2011-09, Vol.37 (9), p.791-797

2011

Volltextzugriff (PDF)

Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS9-02-PS9-02

2021

Volltextzugriff (PDF)

OA22.05 TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S96-S97

2023

Volltextzugriff (PDF)

989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)

Annals of oncology, 2022-09, Vol.33, p.S1005

2022

Volltextzugriff (PDF)

Should Prophylaxis for Pneumocystis carinii Pneumonia in Solid Organ Transplant Recipients Ever Be Discontinued?

Clinical infectious diseases, 1999-02, Vol.28 (2), p.240-246

1999

Volltextzugriff (PDF)

607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A691-A691

2023

Volltextzugriff (PDF)

PP01.17 Sotorasib in Advanced KRAS p.G12C–Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)

Journal of thoracic oncology, 2023-03, Vol.18 (3), p.e17-e17

2023

Volltextzugriff (PDF)

OA03.08 Trilaciclib Reduces the Need for Growth Factors and Red Blood Cell Transfusions to Manage Chemotherapy-Induced Myelosuppression

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.S4-S4

2021

Volltextzugriff (PDF)

Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report

Hormone and metabolic research, 2009-09, Vol.41 (9), p.703

2009

Volltextzugriff (PDF)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage

Cancer, 2006-07, Vol.107 (1), p.136-140

2006

Volltextzugriff (PDF)

Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/ extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival

Breast cancer research and treatment, 2005-09, Vol.93 (2), p.177-188

2005

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(61)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(21)
Humans
(18)
Female
(14)
Oncology
(14)
Male
(11)
Middle Aged
(10)
Chemotherapy
(9)
Adult
(7)
Aged
(7)
Aged, 80 And Over
(6)
Banking Industry
(5)
Cancer
(5)
Cancer Therapies
(5)
Lung Cancer
(5)
Metastasis
(5)
Tumors
(5)
Antineoplastic Agents - Therapeutic Use
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Banks
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Abstract P1-08-18: Impact of gene expression profile testing for lymph node positive (LN+) , hormone receptor positive (HR+), HER2 negative (HER2-) breast cancer (BC) patients on the use of adjuvant chemotherapy in a large community cancer center

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

Tumor Treating Fields (TTFields) Therapy with Standard of Care in Metastatic Non-small Cell Lung Cancer Following Progression on or after Platinum Therapy: Global, Randomized, Pivotal Phase 3 LUNAR Study

Abstract P1-18-13: Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC) participating in the PALOMA trials

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

1418P Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study

7MO Sotorasib in KRAS G12C-mutated advanced non-small cell lung cancer (aNSCLC): Overall survival (OS) data from the global expanded access program (EAP study-436)

Circulating tumor DNA-based genomic profiling of small bowel adenocarcinoma

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810)

Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study

Predictors of clinical outcomes of resected ampullary adenocarcinoma: A single-institution experience

Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens

OA22.05 TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study

989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)

Should Prophylaxis for Pneumocystis carinii Pneumonia in Solid Organ Transplant Recipients Ever Be Discontinued?

607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study

PP01.17 Sotorasib in Advanced KRAS p.G12C–Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)

OA03.08 Trilaciclib Reduces the Need for Growth Factors and Red Blood Cell Transfusions to Manage Chemotherapy-Induced Myelosuppression

Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage

Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/ extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival

Suchergebnisse filtern